285 related articles for article (PubMed ID: 24636863)
1. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.
Ratelade J; Smith AJ; Verkman AS
Exp Neurol; 2014 May; 255():145-53. PubMed ID: 24636863
[TBL] [Abstract][Full Text] [Related]
2. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica.
Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS
Neuropharmacology; 2018 May; 133():345-353. PubMed ID: 29428821
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.
Tradtrantip L; Asavapanumas N; Verkman AS
Mol Pharmacol; 2013 Jun; 83(6):1268-75. PubMed ID: 23571414
[TBL] [Abstract][Full Text] [Related]
4. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.
Ratelade J; Asavapanumas N; Ritchie AM; Wemlinger S; Bennett JL; Verkman AS
Acta Neuropathol; 2013 Nov; 126(5):699-709. PubMed ID: 23995423
[TBL] [Abstract][Full Text] [Related]
5. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
6. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.
Phuan PW; Ratelade J; Rossi A; Tradtrantip L; Verkman AS
J Biol Chem; 2012 Apr; 287(17):13829-39. PubMed ID: 22393049
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Neuromyelitis Optica Immunoglobulin G Binding to Aquaporin-4 by the Small Molecule Blocker Melanthioidine.
Xu H; Gong Y; Jiao Y; Guo J; Zhao L; Yang J; Tong H; Sun M; Li M
Curr Pharm Des; 2023; 29(10):793-802. PubMed ID: 36998134
[TBL] [Abstract][Full Text] [Related]
8. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.
Soltys J; Liu Y; Ritchie A; Wemlinger S; Schaller K; Schumann H; Owens GP; Bennett JL
J Clin Invest; 2019 Apr; 129(5):2000-2013. PubMed ID: 30958797
[TBL] [Abstract][Full Text] [Related]
9. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
[TBL] [Abstract][Full Text] [Related]
10. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity.
Duan T; Smith AJ; Verkman AS
Acta Neuropathol Commun; 2019 Jul; 7(1):112. PubMed ID: 31296268
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model.
Tradtrantip L; Asavapanumas N; Phuan PW; Verkman AS
PLoS One; 2014; 9(9):e106824. PubMed ID: 25191939
[TBL] [Abstract][Full Text] [Related]
13. Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.
Asavapanumas N; Ratelade J; Verkman AS
Acta Neuropathol; 2014 Apr; 127(4):539-51. PubMed ID: 24190619
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.
Rossi A; Ratelade J; Papadopoulos MC; Bennett JL; Verkman AS
Glia; 2012 Dec; 60(12):2027-39. PubMed ID: 22987455
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.
Ratelade J; Verkman AS
Mol Immunol; 2014 Nov; 62(1):104-13. PubMed ID: 24980869
[TBL] [Abstract][Full Text] [Related]
16. Isotetrandrine Reduces Astrocyte Cytotoxicity in Neuromyelitis Optica by Blocking the Binding of NMO-IgG to Aquaporin 4.
Sun M; Wang J; Zhou Y; Wang Z; Jiang Y; Li M
Neuroimmunomodulation; 2016; 23(2):98-108. PubMed ID: 27064690
[TBL] [Abstract][Full Text] [Related]
17. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.
Tradtrantip L; Duan T; Yeaman MR; Verkman AS
J Neuroinflammation; 2019 Mar; 16(1):57. PubMed ID: 30851734
[TBL] [Abstract][Full Text] [Related]
18. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.
Yao X; Verkman AS
Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662
[TBL] [Abstract][Full Text] [Related]
19. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
Ratelade J; Zhang H; Saadoun S; Bennett JL; Papadopoulos MC; Verkman AS
Acta Neuropathol; 2012 Jun; 123(6):861-72. PubMed ID: 22526022
[TBL] [Abstract][Full Text] [Related]
20. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
Tradtrantip L; Zhang H; Saadoun S; Phuan PW; Lam C; Papadopoulos MC; Bennett JL; Verkman AS
Ann Neurol; 2012 Mar; 71(3):314-22. PubMed ID: 22271321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
